Salarius Pharmaceuticals, Inc. (SLRX)
- Previous Close
0.4400 - Open
0.4300 - Bid --
- Ask --
- Day's Range
0.4110 - 0.4825 - 52 Week Range
0.4110 - 1.8100 - Volume
85,596 - Avg. Volume
110,807 - Market Cap (intraday)
1.963M - Beta (5Y Monthly) 0.97
- PE Ratio (TTM)
-- - EPS (TTM)
-2.0200 - Earnings Date Aug 8, 2024 - Aug 12, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
3.25
Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds and Cancer Prevention and Research Institute of Texas for product development activities. The company is headquartered in Houston, Texas.
www.salariuspharma.comRecent News: SLRX
Performance Overview: SLRX
Trailing total returns as of 6/7/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SLRX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SLRX
Valuation Measures
Market Cap
1.96M
Enterprise Value
-2.29M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.54
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-77.36%
Return on Equity (ttm)
-193.68%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-8.92M
Diluted EPS (ttm)
-2.0200
Balance Sheet and Cash Flow
Total Cash (mrq)
4.37M
Total Debt/Equity (mrq)
3.20%
Levered Free Cash Flow (ttm)
-8.54M